Economic Issues in the Treatment of BPH

European Urology, Supplements

Volumn 5, Issue 20, 2006, Pages 1018-1024

  Teillac, Pierre ^a   Scarpa, Roberto M ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

1 Blockers; 5 Reductase inhibitors; BPH; Cost economics; TURP

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; LONG TERM CARE; MICTURITION DISORDER; MONOTHERAPY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

EID: 33750499962     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.08.011     Document Type: Article

References (25)

1. Fraundorfer M.R., Gilling P.J., Kennett K.M., and Dunton N.G. Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study. Urology 57 (2001) 454-458
2. Stoevelaar H.J., and McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics 19 (2001) 131-153
3. McConnell J.D., Roehrborn C.G., Bautista O., et al. The long-term effects of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
4. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., Andriole G., and ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
5. US Census Bureau, International Data Base, April 2005 version, accessed on Dec. 15, 2005 at http://www.census.gov/ipc/www/idbnew.html.
6. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD., accessed on Dec 12, 2005 at http://www.ahrq.gov/HCUPnet/.
7. Barnard C., and Esmond T. DRG-based reimbursement: the use of concurrent and retrospective clinical data. Med Care 19 (1981) 1071-1082
8. Lu-Yao G.L., Barry M.J., Chang C.H., Wasson J.H., and Wennberg J.E. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 44 (1994) 692-698
9. Kobelt G., Spangberg A., and Mattiasson A. The cost of feedback microwave thermotherapy compared with transurethral resection of the prostate for treating benign prostatic hyperplasia. BJU Int 93 (2004) 543-548
10. de la Rosette J.J., Floratos D.L., Severens J.L., Kiemeney L.A., Debruyne F.M., and Pilar Laguna M. Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int 92 (2003) 713-718
11. Boyle P., Roehrborn C.G., Marks L., Vela-Navarette R., and Nickel J.C. The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30≤40 cc and 40 cc. Eur Urol Suppl 2 1 (2003) 160 (abstract 632)
12. Saigal C.S., and Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 173 (2005) 1309-1313
13. Kawakami J., and Nickel J.C. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 6 (1999) 819-822
14. Lowe F.C., McDaniel R.L., Chmiel J.J., and Hillman A.L. Economic modelling to assess the costs of treatment with finasteride, terazosin and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 46 (1995) 477-483
15. Van Exel N.J.A., Koopmanschap M.A., McDonnell J., Chapple C.R., Berges R., and Rutten F.F.H. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 49 (2006) 92-102
16. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557-563
17. Albertsen P.C., Pellissier J.M., Lowe F.C., Girman C.J., Roehrborn C.G., and for the PLESS Study Group. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther 21 (1999) 1006-1024
18. Baladi J.F., Menon D., and Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 9 (1996) 443-454
19. McDonald H., Hux M., Brisson M., Bernard L., and Nickel J.C. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 11 (2004) 2327-2340
20. Holtgrewe H.L., Bay-Neilsen H., Carlsson P., et al. The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In: Dennis L., Griffiths K., Khoury S., et al. (Eds). Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH) (1998), Plymbridge Distributors, Plymouth, United Kingdom 61-81
21. Holtgrewe H.L. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51 (1988) 1-7
22. Lukacs B. Management of symptomatic BPH in France: who is treated and how?. Eur Urol 36 (1999) 14-20
23. Berges R.R., and Pientka L. Management of the BPH syndrome in Germany: who is treated and how?. Eur Urol 36 (1999) 21-27
24. Tubaro A., and Montanari E. Management of symptomatic BPH in Italy: who is treated and how?. Eur Urol 36 (1999) 28-32
25. McNicholas T.A. Management of symptomatic BPH in the UK: who is treated and how?. Eur Urol 36 (1999) 33-39